Pfizer's CEO Is Bullish On Rebate Changes That Could Power New Launches
Executive Summary
Ian Read walked away from a meeting with President Trump with a rosy view on drug pricing and rebate reform. He said he expects rebates will be eliminated, but net drug prices will continue to grow. Rebate reform will benefit new drug launches, he predicted.
You may also be interested in...
Rebate Reform: Big Changes Are Looming For The US Drug Market
Changing US drug rebating policy is like throwing an activated grenade into the middle of the American drug distribution system. Yet, increasingly it seems the US drug market is poised for a big shake up when it comes to the way pharmaceuticals manufacturers price their drugs, negotiate market access with payers, and pay back-end discounts to offset the cost of their products.
Pfizer On Reorganizing, M&A And Investing In Internal R&D
The big pharma's leadership weighs in on why it made sense to organize biosimilars under innovative medicines, why it is investing more in internal R&D, and why tuck-in deals are more appealing than transformative M&A.
Pfizer On Reorganizing, M&A And Investing In Internal R&D
The big pharma's leadership weighs in on why it made sense to organize biosimilars under innovative medicines, why it is investing more in internal R&D, and why tuck-in deals are more appealing than transformative M&A.